CTLA4 and melanoma: In a cohort of 271 patients with melanoma, treatment with sequential anti-CTLA-4 and anti-PD-1 was associated with a better survival outcome than monotherapy with anti-PD-1 or anti-CTLA-4, anti-PD-1 followed by anti-CTLA-4 or dual immunotherapy12.